Scholars Central

Review articlePublished 5 Nov 2013

Developing New Molecules for the Treatment of Painful Diabetic Peripheral Neuropathy: Is it Feasible given the Magnitude of the Placebo Response in Proof of Concept Clinical Studies?

Authors: Domenico Merante, George Skouteris, Rayaz Malik

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Randomised, double blind, placebo controlled studies are necessary in the neuropathic pain clinical research arena. Few drugs are approved for the indication of painful Diabetic Peripheral Neuropathy (DPN): typically these drugs lose their therapeutic response over time and have a far from ideal tolerability risk profile. In addition to that, the response to placebo continues to represent a significant challenge in clinical trials of painful DPN, as well as other neuropathic pain condition. Hence to date few molecules have progressed to phase 3 in painful DPN and even fewer have gained approval. Thus many studies failed because the primary endpoint of statistical superiority to placebo and a clinically relevant reduction of ADPS (Average Daily Pain Score) were not achieved. Any attempt to mitigate the placebo response in this condition may allow future new drugs to successfully progress from Proof of Concept to phase 3 of clinical development and hopefully to their approval. As of today this remains a relevant challenge in a therapeutic area of a well-recognized unmet medical need. The dangers of treating acute and chronic pain with opioids, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or acetaminophen are considerable. By mitigating the placebo response in neuropathic pain clinical trials, this may expedite the discovery, selection and development of improved analgesic treatments for the benefit of public health. In addition, a better understanding of subjects’ typology would be of great help to identify those who really need a more specific pharmacological treatment approach from those subjects who don`t and might benefit instead from alternative non-pharmacological approaches. Magnitude of the Placebo Response in Painful Diabetic Peripheral Neuropathy The pathogenesis of pain in diabetic peripheral neuropathy (painful DPN) involves both peripheral and central mechanisms [1]. The insult of diabetes, in fact, impacts the nervous system from the periphery to the brain. Peripheral mechanisms are due to changes in calcium channel distribution and expression; changes in sodium channel distribution and expression; altered neuropeptide expression; sympathetic sprouting; peripheral sensitization; loss of spinal inhibitory control; altered peripheral blood flow; axonal atrophy, degeneration or regeneration; damage to small fibers; increased glycaemic flux. Central mechanisms include central sensitization; changes in the balance of facilitation/inhibition within descending pathways; increased thalamic vascularity [1,2]. In clinical studies conducted in painful DPN the primary efficacy assessment is typically based upon the 11 point Numerical Rating Pain Scale (NRS) with 0 = no pain and 10 = worst possible pain. Pain can also be measured by the VAS (Visual Analogue Scale), which is a unidimensional validated measure of pain intensity and has been widely used in diverse adult populations, including those with painful DPN. As the NRS scale, for pain intensity, the VAS scale is most commonly anchored by “no pain” (score of 0) and “pain as bad as it could be” or “worst imaginable pain” (score of 100 [100-mm scale]). The pain is assessed by the patients in their daily pain score through paper or electronic diaries. The patients score their pain during the last 24 hours at awakening. Typically the study primary endpoint is the weekly mean pain score at endpoint (=endpoint mean score) often defined as the mean pain score for the last 4/7 available pain diary entries while on study medication. Responder rates are defined as 30% and 50% reduction in pain score as compared to baseline. Numerous secondary efficacy measurement scales can be used in painful DPN studies. These include the Short-Form McGill Pain Questionnaire (SF-MPQ), BPI (Brief Pain Inventory), a Sleep interference scale, the J Diabetes Metab ISSN: 2155-6156 JDM, an open access journal global impression of change by clinician (CGIC), the global impression of change by patient (PGIC), the SF-36 and/or EQ-5D Quality of life Questionnaires, a mood assessment (profile of mood states [POMS] and the Hospital anxiety and depression scale [HADS] and others. The placebo response plays a pivotal role in clinical trials of painful DPN [3]. From an analysis of 70 studies (10,297 patients) conducted specifically in painful DPN, the average response in terms of weighted mean differences was 13.96 (95% CI 11.93 to 15.99) on the Visual Analogue Scale (VAS), utilized as the primary endpoint of the ADPS (Average Daily Pain Score). Placebo accounted for 62% of the response and was significantly higher compared to a parallel analysis carried out on Fibromyalgia (P <0.001), a syndrome also associated with neuropathic pain. From this analysis the placebo response was not associated with age, sex, and race, but indeed with year of study initiation, severity of baseline pain and effect size in active drug groups in both diseases. Thus, significant efficacy in patients receiving placebo may obscure

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • SubjectDiabetes & Endocrinology
  • SubjectNeuroscience & Neurology
  • BylineArticles whose byline prints “Domenico Merante”
  • BylineArticles whose byline prints “George Skouteris”
  • BylineArticles whose byline prints “Rayaz Malik”